Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 901–1,000 of 1,001
Pharmacogenomics of Heart Failure: a Systematic Review
Mottet, F., Vardeny, O., & de Denus, S. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0118 · Cited by 12
Pharmacogenetics in heart failure: promises and challenges
de Boer, R. A., van der Harst, P., van Veldhuisen, D. J., & van den Berg, M. P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903025171 · Cited by 10
“At present, none of these systems has FDA approval, and it is unlikely that these tools will enter the clinic in the next few years.”
BackgroundInfluentialLa insuficiencia cardíaca en el año 2005
Jiménez-Navarro, M. F., Dı́ez, J., Delgado, J. F., & Leiro, M. G. C. (2006) · Revista Española de Cardiología · doi:10.1157/13084449 · Cited by 10
New therapies in acute decompensated heart failure
Gauthier, N., Anselm, A. H., & Haddad, H. A. (2008) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3282f798be · Cited by 10
Beyond Best Practices: Strict Scrutiny as a Regulatory Model for Race-Specific Medicines
Obasogie, O. K. (2008) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2008.296.x · Cited by 13
Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1586-3_17 · Cited by 10
Keys to successful cardiac resynchronization therapy
Herre, J. M. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.01.018 · Cited by 11
The role of racial/ethnic factors in global clinical trials
Ferdinand, K. C., & Igari, M. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1510311 · Cited by 10
Self-citationExiste evidência para tratar insuficiência cardíaca baseada na raça ou etnia?
Latado, A. L., Lopes, M. B., Passos, L. C. S., & Lopes, A. A. (2009) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302009000200010 · Cited by 9
Management of ACCF/AHA Stage C Heart Failure
Adigopula, S., Vivo, R. P., DePasquale, E. C., Nsair, A., & Deng, M. C.-H. K. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.012 · Cited by 10
Current treatment of heart failure with reduction of left ventricular ejection fraction
Aronow, W. S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1242067 · Cited by 10
Raj, L. M., & Adhyaru, B. B. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134378 · Cited by 10
Progress toward genetic tailoring of heart failure therapy.
Lillvis, J. H., & Lanfear, D. E. (2010) · PubMed · Cited by 11
State of Play of Pharmacogenetics and Personalized Medicine in Heart Failure
Parry, H., Doney, A. S. F., Colin N.A. Palmer, & Lang, C. C. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12030 · Cited by 9
Thompson, K. A., Philip, K. J., Barbagelata, A., & Schwarz, E. R. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248410366447 · Cited by 9
Efird, J. T., Kiser, A. C., Crane, P. B., Landrine, H., Kindell, L. C., Nelson, M.-A. M., Jindal, C., Sarpong, D. F., Griffin, W. F., Ferguson, T. B., et al. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1894 · Cited by 9
Hinder, M., Yi, B. A., & Langenickel, T. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1010 · Cited by 10
Representation of Black patients in heart failure clinical trials
Azam, T. U., & Colvin, M. M. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000849 · Cited by 9
“in 2004, the first major heart failure clinical trial conducted exclusively in a single racial group [32].”
BackgroundPharmacologic Therapy for New York Heart Association Class IV Heart Failure
Caccamo, M. A., & Eckman, P. (2011) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00235.x · Cited by 10
Observation Unit Management of Acute Decompensated Heart Failure
Schrock, J. W., & Emerman, C. L. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.08.015 · Cited by 9
“It is not as effective as ACE inhibitors in reducing mortality in patients who have heart failure but may be used in those intolerant of ACE inhibitors and ARBs.93 When used in combination with long-acting nitrates and ACE inhibitors or b-blockers, hydralazine was found to be particularly effective at reducing mortali…”
BackgroundEffectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure
Hammermeister, K. E., Fairclough, D., Emsermann, C. B., Hamman, R. F., Ho, P. M., Phibbs, S., Plomondon, M. E., Valuck, R. J., West, D., & Steiner, J. F. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.03.019 · Cited by 10
The Future of Pharmacogenetics in the Treatment of Heart Failure
Anwar, M. S., Iskandar, Z., Parry, H., Doney, A. S. F., Palmer, C. N., & Lang, C. C. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.120 · Cited by 10
Raina, A., & Kanwar, M. K. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0222-8 · Cited by 9
Subgroup Analyses of Randomized Clinical Trials in Heart Failure: Facts and Numbers
Vidic, A., Chibnall, J. T., Goparaju, N., & Hauptman, P. J. (2016) · ESC Heart Failure · doi:10.1002/ehf2.12093 · Cited by 9
Smooth Muscle Phenotypic Diversity
Fisher, S. A. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.07.003 · Cited by 10
Alanazi, A. (2016) · Journal of Medical Systems · doi:10.1007/s10916-016-0673-4 · Cited by 9
“Furthermore, a study by Taylor et al. (2004) showed that isosorbide dinitrate/hydralazine combination reduced both mortality and hospitalizations by 43 and 39%, respectively in African-American patients with CHF, but not among Caucasian patients [4].”
BackgroundGlobal Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials
Egwim, C., Dixon, B., Ambrosy, A. P., & Mentz, R. J. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0316-1 · Cited by 9
Why We Fail at Heart Failure: Lymphatic Insufficiency Is Disregarded
Houck, P. D., Dandapantula, H. K., Hardegree, E. L., & Massey, J. M. (2020) · Cureus · doi:10.7759/cureus.8930 · Cited by 9
Calamaras, T. D., Pande, S., Baumgärtner, R., Kim, S. K., McCarthy, J. C., Martin, G., Tam, K., McLaughlin, A. L., Wang, G., Aronovitz, M. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.149075 · Cited by 9
“Agents which activate PKG1 through augmentation of cGMP, including nitrates (3), sacubitril/valsartan (4), and vericiguat (5), now represent a rapidly emerging class of drugs which have improved outcomes in heart failure with reduced ejection fraction.”
BackgroundDiversity in modern heart failure trials: Where are we, and where are we going
Anaba, U., Ishola, A., Alabre, A. F., Bui, A., Prince, M., Okafor, H. E., Kola-Kehinde, O. O., Joseph, J. J., Mitchell, D., Odei, B. C. L., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.12.018 · Cited by 9
7. Bidil and Racialized Medicine
Kahn, J. (2011) · Columbia University Press eBooks · doi:10.7312/krim15696-008 · Cited by 9
PHARMACOTHERAPY OF HEART FAILURE
Vittalrao, A. M., Thanusubramanian, H., Kumari, M., & Shaik, A. B. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i6.23712 · Cited by 10
“Results showed 43% decrease in cardiovascular-related death and 33% decrease in the risk associated with HF hospitalization [47].”
BackgroundThe challenges associated with current clinical trials for diastolic heart failure
Thohan, V., & Patel, S. V. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328329f8fd · Cited by 9
Brown, N. J., Muldowney, J. A. S., & Vaughan, D. E. (2006) · Hypertension · doi:10.1161/01.hyp.0000202478.79587.1a · Cited by 9
Executive summary of the African-American Initiative.
Yancy, C. W. (2007) · PubMed Central · Cited by 9
Self-citationRace-specific drugs: regulatory trends and public policy
Winickoff, D. E., & Obasogie, O. K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.008 · Cited by 9
Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons
Aronow, W. S. (2005) · The Journals of Gerontology Series A · doi:10.1093/gerona/60.12.1597 · Cited by 10
“At 10-month follow-up of African Americans with systolic HF, isosorbide dinitrate plus hydralazine significantly reduced mortality by 43% and rate of first hospitalization for HF by 33% (75).”
BackgroundPrevention and Control of Chronic Diseases
McGowan, A., Brownson, R. C., Wilcox, L. S., & Mensah, G. A. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195301489.003.0017 · Cited by 9
Tsai, K. Y., & Tsao, H. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.10.985 · Cited by 9
Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Moran, A. E., & Cooper, R. (2005) · New England Journal of Medicine · doi:10.1056/nejm200503103521018 · Cited by 9
The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management
Alvi, A., Singamala, H., Gadde, S. S. V., & Javvaji, C. K. (2026) · Cureus · doi:10.7759/cureus.100993 · Cited by 11
Improving care for patients with heart failure: What can Taiwan accomplish?
Chen, S., Chen, M., & Tang, W. H. W. (2007) · Zhōnghuá mínguó xīnzàngxué huì zázhì · Cited by 8
Racial differences and mortality risk in patients with heart failure and hyponatremia
Miles, J. A., Quispe, R., Mehlman, Y., Patel, K., von Buchwald, C. L., You, J. Y., Sokol, S. I., & FAILLACE, R. T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218504 · Cited by 8
“First, our results reflect the idea that a) hyponatremia is closely linked to excessive activation of RAAS and b) RAAS activity has been shown to differ depending on one’s race.[7, 16] For example, African Americans have lower baseline renin levels compared to whites and Hispanics have been shown to have higher plasma…”
ResultTereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Rimskaya, E. M., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-2-6-76 · Cited by 8
Pharmacologic management of patients with both heart failure and diabetes
MacDonald, M. R., Petrie, M. C., Fisher, M., & McMurray, J. J. V. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0019-3 · Cited by 9
Heart Failure in Women Due to Hypertensive Heart Disease
Ballard‐Hernandez, J., & Itchhaporia, D. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.002 · Cited by 8
Team-Based Care for Managing Cardiac Comorbidities in Heart Failure
Bellam, N., Kelkar, A. A., & Whellan, D. J. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.03.005 · Cited by 9
The Coming of Age of Multicultural Medicine
McBride, G. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020062 · Cited by 8
“The report painted a bleak picture of the quality of health care afforded to African-Americans and other racial and ethnic minorities.”
InfluentialVerbrugge, F. H., Dupont, M., Finucan, M., Gabi, A., Hawwa, N., Müllens, W., Taylor, D. O., Young, J. B., Starling, R. C., & Tang, W. H. W. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.324 · Cited by 8
van Heerebeek, L. (2014) · SOJ Pharmacy & Pharmaceutical Sciences · doi:10.15226/2374-6866/1/2/00112 · Cited by 11
“Conversely, chronic use of isosorbide dinitrate combined with the antioxidant hydralazine improved outcome in V-HeFT I and A-HeFT trials [205,206].”
BackgroundNguyen, E., Weeda, E. R., & White, C. M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.677 · Cited by 9
Rethinking end-points for bone-targeted therapy in advanced cancer
García, S. G., Clemons, M. J., & Amir, E. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.014 · Cited by 8
“The use of composite end-points in branches of medicine such as cardiology is prevalent [17,18].”
BackgroundDesroche, L., Milleron, O., Safar, B., Ou, P., Garbarz, É., Badie, Y. L., Abtan, J., Millischer, D., Pathak, A., Durand‐Zaleski, I., et al. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.09.005 · Cited by 8
Clinical Pharmacology of Antihypertensive Therapy
Taylor, A. A., & Pool, J. L. (2005) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.02.006 · Cited by 10
Self-citationPapel de los nitratos en el tratamiento de la enfermedad cardiovascular
de Sá, E. L., Estévez, Á., Onaindia, J. J., Rubio, R., & Lopez-Sendon, J. L. (2006) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(06)74819-1 · Cited by 9
Diabetes and prognosis: are systolic and diastolic heart failure different?: Table 1
Kamalesh, M. (2008) · Heart · doi:10.1136/hrt.2008.152686 · Cited by 8
Sani, M. U., Damasceno, A. A. M., Davison, B. A., Cotter, G., Mayosi, B. M., Edwards, C., Azibani, F., Adam, T., Arif, G., Jessen, N., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13032 · Cited by 8
The impact of race on response to RAAS inhibition
Wallace, T. W., & Drazner, M. H. (2005) · Current Heart Failure Reports · doi:10.1007/s11897-005-0012-4 · Cited by 8
Personalised medicine: who is an Asian?
Po, A. L. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60793-4 · Cited by 8
Stevenson, L. W., & Lewis, E. F. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.054 · Cited by 8
Tang, W. H. W., & Francis, G. S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.018 · Cited by 8
The Management of Co-Morbidities in Patients with Heart Failure – Hypertension
Coats, A. J. S., Rosano, G. M. C., & Lopatin, Y. M. (2017) · International Cardiovascular Forum Journal · doi:10.17987/icfj.v10i0.452 · Cited by 7
KELTY, M. F., Bates, A., & Pinn, V. W. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382167-6.00013-8 · Cited by 7
Increased Long-Term Mortality among Black CABG Patients Receiving Preoperative Inotropic Agents
Efird, J. T., Griffin, W. F., Sarpong, D. F., Davies, S., Vann, I., Koutlas, N. T., Anderson, E. J., Crane, P. B., Landrine, H., Kindell, L. C., et al. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120707478 · Cited by 7
“Our findings are important to contrast with the African-American Heart Failure Trial (A-HeFT) [24] of combination isosorbide dinitrate and hydralazine in black patients.”
ResultStatistical challenges in a regulatory review of cardiovascular and CNS clinical trials
Hung, H., Wang, S., Yang, P., Jin, K., Lawrence, J., Kordzakhia, G., & Massie, T. (2015) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1092025 · Cited by 7
“For instance, the A-HeFT study (Taylor et al., 2004) employed such an adaptive statistical information design using a completely prespecified algorithm for unblinded sample size reestimation to handle the new primary composite endpoint with little prior experience.”
MethodMolecular imaging targets of cardiac remodeling
Shirani, J., & Dilsizian, V. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0022-z · Cited by 7
Tsai, E. J., Wilkoff, B. L., Mitchell, J. E., Peterson, P. N., Riegel, B. J., Sam, F., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., et al. (2013) · Cited by 7
Self-citationThe role of venodilators in the perioperative management of heart failure
Valchanov, K. P., & Arrowsmith, J. E. (2012) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835016be · Cited by 7
Practical Pharmacogenomic Approaches to Heart Failure Therapeutics
Krittanawong, C., Namath, A. G., Lanfear, D. E., & Tang, W. H. W. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0483-5 · Cited by 7
“In the African American Heart Failure Trial (A-HeFT) [50], a double-blind randomized trial of 1050 African American patients with NYHA class III or IV heart failure, African American patients had a lower mortality rate on IDN/H, compared to the placebo group.”
BackgroundA Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure
Iyngkaran, P., Toukhsati, S. R., Thomas, M. C., Jelinek, M. V., Hare, D. L., & Horowitz, J. D. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s38444 · Cited by 7
Ural, D., KANDEMİR, A. Ş., Karaüzüm, K., Baydemır, C., Karaüzüm, İ., Bozyel, S., Kozdağ, G., & Ağır, A. A. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.02.006 · Cited by 8
Managing hypertension in patients with heart failure
Gupta, T., Rezan, T., & Krim, S. R. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000634 · Cited by 7
Gupta, K., Spertus, J. A., Birmingham, M. C., GOSCH, K. L., Husain, M., Kitzman, D. W., Pitt, B., Shah, S. J., Januzzi, J. L., Lingvay, I., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063263 · Cited by 7
Ajay, A., Rasoul, D., Abdullah, A., En, B. L. W., Mashida, K., Al-Munaer, M., Ajay, H., Duvva, D., Mathew, J., Adenaya, A., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2290064 · Cited by 8
“Addition of hydralazine/nitrate to standard HF treatment has shown to improve survival in black patients with advanced heart failure [121].”
BackgroundEurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., Yasui, Y., & Johnson, J. A. (2010) · PubMed Central · Cited by 7
Now we are talking sense! Functional approaches to novel nutraceuticals and cosmeceuticals
Krohn, M., Kleber, A., Schaffar, G., Dechert, U., & Eck, J. (2008) · Biotechnology Journal · doi:10.1002/biot.200700204 · Cited by 7
“This is a trend that has been already applied in FDA-approved pharmaceutical drug development, as exemplified by the anti-breast cancer drug herceptin, an antibody which is administered in case of genotype-tested overexpression of the HER2 receptor [36] or the drug treatment with BiDil (isosorbide dinitrate/hydralazin…”
MethodCharacterization of New Organic Nitrate Hybrid Drugs Covalently Bound to Valsartan and Cilostazol
Knorr, M., Hausding, M., Schulz, E., Oelze, M. W., Rümmler, R., Schuff, A., Daub, S., Schreiner, J., Kröller‐Schön, S., Wenzel, P., et al. (2012) · Pharmacology · doi:10.1159/000339861 · Cited by 8
Pharmacologic Options for Treatment of Ischemic Disease
Schroeder, J. S., Frishman, W. H., Parker, J. D., Angiolillo, D. J., Woods, C. E., & Scirica, B. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00007-2 · Cited by 11
Unidades de insuficiência cardíaca: estado da arte na abordagem da insuficiência cardíaca
Timóteo, A. T., Pereira‐da‐Silva, T., Moreira, R. I., Gonçalves, A., Soares, R. M., & Ferreira, F. (2020) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2020.02.007 · Cited by 11
Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology
Brown, S.-A. N., Zaharova, S., Mason, P., Thompson, J., Thapa, B., Ishizawar, D. C., Wilkes, E., Ahmed, G., Rubenstein, J., Sanchez, J., et al. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.568720 · Cited by 7
Modulation of Arterial Stiffness Gradient by Acute Administration of Nitroglycerin
Fortier, C., Garneau, C.-A., Paré, M., Obeid, H., Côté, N., Duval, K., Goupil, R., & Agharazii, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.774056 · Cited by 7
Listerman, J., Geisberg, C. A., Nading, M. A., Goring, J., Huang, R. L., & Butler, J. (2007) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2007.05948.x · Cited by 8
Baliga, R. R., Dec, G. W., & Narula, J. (2013) · Global Heart · doi:10.1016/j.gheart.2013.05.002 · Cited by 7
Fixed-Dose Isosorbide Dinitrate-Hydralazine: Race-Based Cardiovascular Medicine Benefit or Mirage?
Ferdinand, K. C. (2008) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2008.291.x · Cited by 7
Self-citationKrzysztofik, J., & Ponikowski, P. P. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1299574 · Cited by 8
“hypotension, headache, dizziness, nausea, arthralgia, and lupus-like syndrome) [4,27,29,55].”
Alterations in Ventricular Structure
Anand, I. S., & Florea, V. G. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5895-3.10015-4 · Cited by 9
Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?
Bernardez‐Pereira, S., Ramires, F. J. A., de Melo, R. F. T., & Pereira-Barretto, A. C. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000193 · Cited by 7
Stevens, E. R., Farrell, D., Jumkhawala, S. A., & Ladapo, J. A. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.06.013 · Cited by 7
Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure
Steinberg, B. A., & Piccini, J. P. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.01.013 · Cited by 8
Effect of nitroglycerin on splanchnic and pulmonary blood volume
Okamoto, L. E., Dupont, W. D., Biaggioni, I., & Kronenberg, M. W. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02811-7 · Cited by 8
Molecular Signature Analysis: the Potential of gene-expression Analysis in Cardiomyopathy
Kittleson, M. M., & Hare, J. M. (2005) · Future Cardiology · doi:10.2217/14796678.1.6.793 · Cited by 7
“• The benefit of combination therapy with isosorbide dinitrate and hydralazine may be greater in black heart-failure patients [72]”
BackgroundUpdate in the Approach to and Management of Heart Failure
Gelow, J. M., & Fang, J. C.-T. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000224752.85714.11 · Cited by 7
“02).(66) Combination therapy with isosorbide dinitrate and hydralazine can be considered for patients with NYHA class III or IV HF already on RAS antagonists and beta blockers.”
BackgroundMonitoring Adherence to Guidelines
Cohn, J. N. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.795294 · Cited by 7
Self-citationMarkham, D. W., Dries, D. L., King, L. P., Leonard, D. S., Yancy, C. W., Peshock, R. M., Willett, D. L., Cooper, R., & Drazner, M. H. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.11.038 · Cited by 9
Self-citationWarshauer-Baker, E., Bonham, V. L., Jenkins, J., Stevens, N. G., Page, Z., Odunlami, A. O., & McBride, C. M. (2008) · Public Health Genomics · doi:10.1159/000133307 · Cited by 7
“may help give information about what is needed to improve the perceived clinical utility of family history.Lastly, although not a primary focus of this study, our results raise questions about physicians’ attitudes regarding insurance status that could be explored in future research. Insurance status was rated as leas…”
ResultFurther Comments on the Alpha-Spending Function
Lan, K. K. G., & DeMets, D. L. (2009) · Statistics in Biosciences · doi:10.1007/s12561-009-9004-3 · Cited by 7
Heart Failure and Cardiomyopathy
Litwin, S. E., & Benjamin, I. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6109-0.00006-x · Cited by 7
The year in heart failure: 2004
Massie, B. M. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.01.001 · Cited by 7
Singh, S. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000197302.13225.08 · Cited by 7
Pharmacogenetics and ethnically targeted therapies
Kahn, J. (2005) · BMJ · doi:10.1136/bmj.330.7506.1508-a · Cited by 7
“The authors assert that the major implication of BiDil is that differential responses to treatment between racial groups are attributed primarily to genetic differences. Unfortunately, this is precisely not the major medical implication of BiDil, but rather the major popular misreading of BiDil. The A-HeFT trials, on…”
Background
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.